Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amylyx Pharmaceuticals excels in Q4 with RELYVRIO launch success

Amylyx Pharmaceuticals demonstrated strong financial performance in Q4 2022, driven by the successful commercial launch of RELYVRIO for ALS treatment.
The company's focus on key priorities for the U.S. launch and commitment to serving ALS patients position it well for future growth and impact.
While facing challenges in meeting analyst expectations and study success criteria, Amylyx Pharmaceuticals remains optimistic about the opportunities ahead in advancing ALS treatment.

Amylyx Pharmaceuticals achieves profitability in Q1, plans global PSP study

Amylyx Pharmaceuticals delivered strong financial performance in Q1, driven by the success of RELYVRIO and plans for AMX0035 in PSP. While facing challenges in profitability expectations and pipeline expansion, the company is well-positioned to capitalize on opportunities for growth and impact.

Amylyx Pharmaceuticals reports robust Q2 performance and strategic growth focus

Amylyx Pharmaceuticals' Q2 2023 Earnings Call highlighted strong financials, patient-centric initiatives, and advancements in R&D programs for neurodegenerative diseases.
Analysts' inquiries underscored the need for clarity on compliance rates, expansion strategies, and study design considerations to address potential challenges.
The company's emphasis on trial design strength, patient support, and market positioning opportunities signals a strategic focus on growth and innovation.

Amylyx Pharmaceuticals reports strong Q3 earnings, eyes growth opportunities

Amylyx Pharmaceuticals had a strong Q3 performance with significant net product revenues and a focus on expanding patient reach. While facing challenges in discontinuations and revenue impact, the company is optimistic about growth opportunities through education and trial results.

Amylyx Pharmaceuticals reports robust earnings, poised for market expansion

Amylyx Pharmaceuticals had a successful year financially, with strong revenue growth and a solid financial position.
The company's focus on expanding market reach, developing innovative biomarkers, and enhancing disease diagnosis underscores their commitment to advancing ALS treatment.
While facing uncertainties with upcoming trial data and regulatory challenges, Amylyx remains optimistic about growth opportunities and R&D advancements.

Amylyx Pharmaceuticals adapts strategy post-PHOENIX trial, eyes regulatory milestones

Amylyx Pharmaceuticals navigated a challenging quarter with a focus on pipeline diversification and strategic planning for multiple neurodegenerative diseases. Despite setbacks in the PHOENIX trial, the company remains resilient and proactive in addressing challenges while seizing opportunities for growth and regulatory progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Games & Esports Experience Acquisition Corp

Hour Loop

Modiv

Smart for Life Inc

Talon 1 Acquisition Corp

Vigil Neuroscience

Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes.

These Were the 10 Worst Performing IPOs in Q1 2022

Biogen

bluebird bio

Bristol-Myers

Gilead Sciences

TG Therapeutics

If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock price but also a company's future.

5 Key FDA Decisions Could Affect Drug Stocks

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals today announced the presentation of safety and tolerability data on AMX0035 as assessed in the CENTAUR and PEGASUS trials.

Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting

On March 30, FDA's advisory committee voted 6 No to 4 Yes, to the question if AMLX's single phase 2 trial data established its effectiveness in treating ALS.

Amylyx's ALS Drug Application Hangs In The Balance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals today reported financial results for the full year ended December 31, 2021

Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals announced the outcome of the U.S. FDA's Advisory Committee meeting to review the NDA for AMX0035 for the treatment of ALS

Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS

The FDA's currently looking at an application for the company's lead candidate.

Could Amylyx Pharmaceuticals Have a Blockbuster ALS Treatment?

The FDA released its briefing documents for the advisory committee to discuss Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) sodium phenylbutyrate/taurursodiol (AMX0035) powder for amyotrophic lateral sclerosis (ALS). Agency statisticians called into question the Company's.

Amylyx Shares Plummet On Skeptical FDA Adcomm Docs On ALS Drug

It seems the FDA isn't going to approve the company's ALS drug before an ongoing phase 3 trial produces evidence of efficacy.

Here's Why Amylyx Pharmaceuticals Stock Is Getting Hammered on Monday

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals today announced that the U.S. FDA posted briefing documents for its March 30, 2022 Advisory Committee meeting

Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx launches an Expanded Access Program (EAP) for AMX0035 in the U.S. for people living with ALS that meet program eligibility criteria.

Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035

Akebia Therapeutics

Arena Pharmaceuticals

Ascendis Pharma

IMARA

Terns Pharmaceuticals

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts in March

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx' MAA to the European Medicines Agency's (EMA) CHMP for AMX0035 for the treatment of ALS has been validated and is now under CHMP review.

Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals today announced the appointment of Gina M. Mazzariello to Chief Legal Officer (CLO) and General Counsel.

Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx today announced that a meeting of the U.S. FDA Advisory Committee to review the NDA for AMX0035 has been scheduled for March 30, 2022.

Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 4:20pm ET.

Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CALGARY, Alberta & TORONTO--(BUSINESS WIRE)--CNDR and Amylyx Pharmaceuticals are partnering on a real‐world evidence generation initiative for Amylyx' novel investigational therapy AMX0035.

The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS

CinCor Pharma

Should you add these stocks to your portfolio?

New Year, Fresh Stocks: 3 IPOs That Joined the Market in January

Andreas Halvorsen (Trades, Portfolio), chief investment officer of Viking Global Investors, disclosed a stake in Amylyx Pharmaceuticals Inc. ( AMLX , Financial) late last week.

Andreas Halvorsen Gets in on Amylyx Pharmaceuticals Following IPO

The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Four SPACs went public led by Sagansky and Sloan's Screaming Eagle Acquisition, which raised $750 million.

U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week

Amylyx Pharmaceuticals raised $190 million, CinCor Pharma collected nearly $194 million, and Vigil Neuroscience came in at $98 million.

The Year's First Three IPOs All Went 'Clunk.' This Is Why.

Three Biotech IPOs Started Trading. Here's How the Stocks Did.

Three biotechs launched their offerings on Monday, set to be the first IPOs of the new year. Amylyx is developing oral small molecule therapies for amyotrophic lateral sclerosis and a broad range of neurodegenerative diseases.

2022 IPO Market Kicks Off With 3 Biotechs Set To Trade On Friday

Amylyx Pharmaceuticals is developing combo therapies to reduce neuronal death in ALS and other neurodegenerative diseases by targeting multiple destructive pathways.

Amylyx Pharmaceuticals: Targeting Multiple Destructive Pathways To Reduce Neuronal Death

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx today announced the launch of its initial public offering of 8,750,000 shares of common stock pursuant to a registration statement on Form S-1.

News for Amylyx Pharmaceuticals Stock (AMLX)